Authored by Karl Simpson
Cancer immunotherapy is a hot topic and is in the cross-hairs of many investors and pharma companies. UK biotech, Scancell Holdings, is developing novel immunotherapies for the treatment of cancer based on ImmunoBody® and Moditope®, the company’s technology platforms. The company’s lead product from these platforms, SCIB1 ImmunoBody®, is indicated for metastatic melanoma and is currently in Phase I/II clinical trials. SCIB1 immunobody recently received FDA Orphan Drug Designation. Initial data from the trial demonstrates that SCIB1 produced a melanoma-specific immune response and promising survival trend.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumor site, and the cytoxic T-lymphocyte or CTL response where the immune system cells are primed to recognise and kill specific cells.
The company has also identified and patented a series of epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity.
Liftstream is an executive search and interim management recruitment company working exclusively within the global life science sector. Liftstream is proud to support rare disease day 2014.
